[ERCC1 expression as a predictor of survival after operation in stage I non-small cell lung cancer patients]

[Change of ERCC1 expression of residual VX2 squamous carcinoma cells in rabbit lung after radiofrequency ablation]

背景与目的

残存肿瘤是影响射频消融（radiofrequency ablation, RFA）治疗肺恶性肿瘤效果的重要因素，联合铂类药物化疗是减少残存肿瘤的重要手段之一。核苷酸切除修复交叉互补基因1（excision repair cross-complementation group 1, ERCC1）的表达水平是影响铂类药物化疗效果的重要因素之一。RFA治疗后残存肿瘤会发生一些生物学特性变化，但有关ERCC1表达变化的研究尚无报道。本研究旨在探讨RFA治疗后兔肺内残存VX2鳞癌细胞ERCC1表达水平的变化。

方法

应用组织块悬液注射法建立兔VX2鳞癌肺内移植瘤模型。58只荷瘤新西兰白兔随机分为对照组（n=10）和RFA组（n=48）。在RFA治疗时，通过控制电极展开范围、输出功率、治疗时间的方法，造成肿瘤残存。应用免疫组织化学方法检测残存肿瘤细胞在不同时间点ERCC1表达的阳性率。

结果

RFA组残存肿瘤组织ERCC1表达阳性率在1 d-5 d呈一过性升高（53.7%±1.6% & 32.9%±2.5%），5 d后恢复至对照组水平。

结论

因在RFA治疗后1 d-5 d内残存肿瘤细胞ERCC1表达增高，在此期间给予铂类药物化疗可能效果不佳。

MicroRNA gene dosage alterations and drug response in lung cancer

Chemotherapy resistance is a key contributor to the dismal prognoses for lung cancer patients. While the majority of studies have focused on sequence mutations and expression changes in protein-coding genes, recent reports have suggested that microRNA (miRNA) expression changes also play an influential role in chemotherapy response. However, the role of genetic alterations at miRNA loci in the context of chemotherapy response has yet to be investigated. In this study, we demonstrate the application of an integrative, multidimensional approach in order to identify miRNAs that are associated with chemotherapeutic resistance and sensitivity utilizing publicly available drug response, miRNA loci copy number, miRNA expression, and mRNA expression data from independent resources. By instigating a logical stepwise strategy, we have identified specific miRNAs that are associated with resistance to several chemotherapeutic agents and provide a proof of principle demonstration of how these various databases may be exploited to derive relevant pharmacogenomic results.